Ruben Mesa, MD, of UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, describes novel developments in the treatment of myloproliferative neoplasms (MPNs) including the development of IMG-7289 for essential thrombocythemia (ET) and myelofibrosis as well as studies evaluating ropeginterferon alfa-2b for both ET and polycythemia vera. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).